

# Alessandra Cataldo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3297209/publications.pdf>

Version: 2024-02-01

14  
papers

498  
citations

932766

10  
h-index

1058022

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

947  
citing authors

#	ARTICLE	IF	CITATIONS
1	What if the future of HER2â€­positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTO study. <i>Cancer Medicine</i> , 2022, 11, 332-339.	1.3	6
2	Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay. <i>Cancers</i> , 2021, 13, 3691.	1.7	20
3	Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. <i>Cancers</i> , 2021, 13, 4081.	1.7	5
4	miR-205 in Breast Cancer: State of the Art. <i>International Journal of Molecular Sciences</i> , 2021, 22, 27.	1.8	33
5	miR-9-Mediated Inhibition of EFEMP1 Contributes to the Acquisition of Pro-Tumoral Properties in Normal Fibroblasts. <i>Cells</i> , 2020, 9, 2143.	1.8	13
6	MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2261.	1.7	12
7	MicroRNA and Oxidative Stress Interplay in the Context of Breast Cancer Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5143.	1.8	30
8	MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer. <i>Breast</i> , 2018, 39, 46-52.	0.9	11
9	MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers. <i>Frontiers in Oncology</i> , 2018, 8, 352.	1.3	13
10	MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. <i>Oncotarget</i> , 2018, 9, 27920-27928.	0.8	14
11	Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. <i>Cell Death and Disease</i> , 2016, 7, e2312-e2312.	2.7	232
12	miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. <i>Oncotarget</i> , 2016, 7, 786-797.	0.8	70
13	High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors. <i>Journal of Translational Medicine</i> , 2013, 11, 25.	1.8	18
14	Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation. <i>PLoS ONE</i> , 2013, 8, e58849.	1.1	21